The main aim of this thesis is to provide a comprehensive account of the development of the institution of slavery in Korea. Slavery was a part of Korean society from its earliest times, and the evidence of this can be found in the penal code of eight provisions enacted by the mythical emperor Kidža, where he for the first time mentioned slavery as a punishment for theft. From this time on it was ceaselessly present in Korean society until its abolition in 1894. The oldest form of slavery as a punishment was gradually supplemented with other ways of how a person could fall into slavery. Individual slavery gradually evolved into hereditary slavery. Despite the fact that slavery was ceaselessly present in Korean society, the character and even the existence of it are still called into question in academic discussions. In the introductory part of my thesis I focused on the very essence of slavery. Afterwards, I gave a brief overview of the characteristics of three typical slave societies i.e. ancient Greece, ancient Rome and the United States of America. Studying the important characteristics of slavery in other slave societies provided the base for a detailed analysis of the connections with the Korean type of slavery. Some of this information confirms the hypothesis that slavery in Korea was...

No description available.

A incidência do melanoma, tumor maligno que se origina dos melanócitos, vem crescendo em todo o mundo. História familial positiva da doença tem sido relatada em 8 a 14% dos pacientes afetados. Muitos estudos sugeriram o envolvimento da região 9p21, onde se encontra o gene CDKN2A, no surgimento dessa neoplasia. Este é um gene supressor tumoral clássico e a inativação dos dois alelos tem sido detectadas em linhagens celulares tumorais de famílias com melanoma hereditário e esporádico. Mutações em linhagens germinativas do gene CDKN2A têm sido identificadas em aproximadamente 20% das famílias com melanoma familial. Utilizando técnicas de biologia molecular como Reação em Cadeia da Polimerase (PCR), Conformação Estrutural de Fita Simples (SSCP) e seqüenciamento, este projeto estudou 22 pacientes com critérios clínicos de melanoma hereditário e encontrou uma mutação (P48T) em um paciente numa família de três afetados. Em 13 casos foi identificado pelo menos um dos três polimorfismos: 500 C>G (31,9%), 540 C>T (27,3%) e A148T (4,5%). Os resultados demonstram a importância da pesquisa de mutações no gene CDKN2A principalmente em famílias com dois ou mais membros afetados pela doença. / The incidence of melanoma, malign tumor that originates from melanocytes, is increasing all over the world. Positive familial history of disease has been related in 8 to 14% of affected patients. Several studies have suggest the 9p21 region evolvement, where is located the CDKN2A gene, in the arising of this neoplasia. It is a classic tumor suppressor gene and the inactivation of two alleles has been detected in tumor cells lines of families with hereditary and sporadic melanoma. Nowadays germeline mutations in CDKN2A gene have been identified in almost 20% of families with familial melanoma. Using molecular biology techniques like Polymerase Chain Reaction (PCR), Single Strand Conformational Polymorphism (SSCP) and sequencing, this project studied 22 patients with clinical pattern of hereditary melanoma and it found one mutation (P48T) in one patient belonged to a three affected family. Thirteen cases had at least one of the three polymorphisms: 500 C>G (31,9%), 540 C>T (27,3%) e A148T (4,5%). The results show the importance of the search for mutations in the CDKN2A gene mainly in families with two or more affected by disease.

A audição representa a principal fonte para o aprendizado da fala e linguagem durante a infância e a surdez e a privação de estímulos auditivos pode implicar em dificuldades emocionais e sociais àqueles indivíduos afetados. Aproximadamente 360 milhões de pessoas sofrem de perda auditiva no mundo, o que corresponde a 5,3% da população mundial. A surdez pode se desenvolver em decorrência de causas genéticas (hereditárias), não-genéticas e ambientais. As infecções pré-natais e a exposição a ruídos constituem as causas ambientais mais comuns. Já a surdez hereditária, constitui o transtorno neurossensorial mais comum em humanos, com uma prevalência de 1:1000 nascidos vivos. Mais de 70% dos casos de surdez hereditária constituem casos não-sindrômicos, destes cerca de 70% cursam com surdez congênita ou pré-lingual. Na maioria dos casos, a perda auditiva hereditária é neurossensorial, heterogênea, com diferentes padrões de herança e com uma grande quantidade de genes envolvidos. Estudos têm demonstrado o importante papel dos genes GJB2, GJB6 e SLC26A4 na fisiologia do ouvido interno e alterações nestes genes têm sido relatadas como causa da surdez hereditária. Desta forma, o objetivo deste estudo foi investigar a base genética e o papel do gene SLC26A4 na perda auditiva neurossensorial (PANS) nãosindrômica pré-lingual em pacientes atendidos pelo serviço de Genética Médica do Hospital das Clínicas de Ribeirão Preto. Para isso, uma série de 88 casos foi investigada quanto a características clínicas e moleculares. A amostra abrangeu indivíduos de ambos os sexos, com idade de 2 a 63 anos, provenientes de 88 famílias diferentes, assistidos durante o período de 2003 a 2013. As amostras foram triadas pela técnica de High Resolution Melting (HRM) e em seguida levadas para o seqüenciamento para caracterização das alterações. Na série de casos estudada, 23,9% (21/88) dos pacientes portadores de surdez neurossensorial não-sindrômica pré-lingual evidenciaram alterações nos genes GJB2, GJB6 e SLC26A4 sugeridas como patogênicas. A prevalência de alterações no gene SLC26A4 foi de 28,4% (25/88), não relacionada à Síndrome do Aqueduto Vestibular Alargado (SAVA). Dentre as 11 alterações encontradas neste gene, três constituem mutações não descritas: p.Gly139Arg, p.Ile254Val, p.Asn382Lys. Os genótipos mais freqüentes neste estudo foram a c.35delG/c.35delG no gene GJB2 (5/88), a dupla heterozigose com o gene GJB6 c.35delG/del(GJB6-D13S1854) (3,4%) e chr7:g.107301238C>G/wt no gene SLC26A4 (10,2%). Entretanto, apenas 19,3% dos indivíduos apresentaram genótipos sugeridos como responsáveis pelo fenótipo estudado. Alterações particulares no gene SLC26A4 podem sugerir a explicação para a surdez genética para aproximadamente 9,1% destes casos. Destes, cinco casos de heterozigose preditas como patogênicas (p.Ile300Leu; p.Asn324Tyr e p.Asn382Lys), dois casos de heterozigose composta (chr7:g.107301201T>C/chr7:g.107301238C>G e chr7:g.107301238C>G/p.Gly139Arg) e um caso de dupla heterozigose com GJB2 (chr7:g.107301238C>G/c.35delG). Isto ressalta a importância do gene SLC26A4 para o diagnóstico molecular de surdez hereditária e reforça a sua potencial contribuição para o processo de aconselhamento genético. Entretanto, nossos dados sugerem a necessidade de testes funcionais a fim de elucidar o papel destas alterações para o estabelecimento do fenótipo, como também, a presença de outros genes ou regiões envolvidas naqueles casos em que mutações monoalélicas não foram suficientes para justificar o fenótipo. / The hearing is the main source for learning speech and language during childhood and deafness and deprivation of auditory stimuli can result in emotional and social difficulties to those affected individuals. Approximately 360 million people suffer from hearing loss worldwide which corresponds to 5.3% of the world population. Deafness may develop due to genetic (hereditary), non-genetic and environmental causes. Prenatal infections and exposure to noise are the most common environmental causes. Hereditary deafness is the most common sensorineural disorder in humans, with a prevalence of 1:1000 live births. More than 70% of hereditary deafness cases are nonsyndromic, about 70% of these occur with congenital or prelingual deafness. In most cases, inherited sensorineural hearing loss is heterogeneous, with different patterns of inheritance and with a large number of genes involved. Studies have shown the important role of genes GJB2, GJB6 and SLC26A4 in the physiology of the inner ear and changes in these genes have been reported as cause of hereditary hearing loss. Thus, the aim of this study was to investigate the genetic basis and the role of SLC26A4 gene in non-syndromic prelingual sensorineural hearing loss (SNHL) in patients enrolled in the Medical Genetics Service of Hospital das Clínicas de Ribeirão Preto. For this, a series of 88 cases were submitted to a clinical and molecular investigation. The sample consisted of individuals of both sexes, aged 2-63 years from 88 different families, assisted during the period 2003-2013. The samples were screened by the technique of High Resolution Melting (HRM) and then taken for sequencing to characterize the mutations. In the series of cases studied, 23.9% (21/88) of patients with non-syndromic prelingual sensorineural deafness showed variants in genes GJB2, GJB6 and SLC26A4 suggested as pathogenic. The prevalence of mutations in the SLC26A4 gene was 28.4% (25/88), not related to non-syndromic EVA. Among the 11 mutations found in this gene, three are reported as novel mutations: p.Gly139Arg, p.Ile254Val, p.Asn382Lys. The most frequent genotypes found in this study were the c.35delG/c.35delG in GJB2 gene (5/88), the double heterozygosity with GJB6 gene c.35delG/del(GJB6-D13S1854) (3,4%) and chr7:g.107301238C>G/wt in the SLC26A4 gene (10,2%). However, only 19.3% of subjects presented genotypes suggested as responsible for the studied phenotype. Particular mutations in the SLC26A4 gene may suggest the explanation for the genetic deafness to approximately 9.1% of these cases. Of these, five cases of heterozygosity predicted as pathogenic (p.Ile300Leu; p.Asn324Tyr and p.Asn382Lys), two cases of compound heterozygosity (chr7:g.107301201T>C/chr7:g.107301238C>G and chr7:g.107301238C>G/p.Gly139Arg) and one case of double heterozygosity with GJB2 gene (chr7:g.107301238C>G/c.35delG). Those data highlights the importance of the SLC26A4 gene for molecular diagnosis of hereditary hearing loss and give strength to its potential contribution to the genetic counseling process. However, our data suggest the need for functional tests in order to elucidate the role of these changes to the phenotype, as well as the presence of other genes or regions involved in those cases that monoallelic mutations were not sufficient to justify the phenotype.

INTRODUÇÃO: O angioedema hereditário (AEH) é uma doença rara, causada pela deficiência do inibidor de C1 esterase (C1-INH), que se manifesta por ataques recorrentes e imprevisíveis de edema em face, extremidades, genitais, tronco e trato gastrintestinal. O edema em vias superiores pode levar a asfixia e morte; enquanto que as crises de dor abdominal podem conduzir à laparatomias desnecessárias. Por suas características, o AEH afeta profundamente a qualidade de vida (QV) de seus portadores, tanto na esfera física, como psicológica e social. O presente estudo teve como objetivo avaliar a qualidade de vida relacionada à saúde destes pacientes. MÉTODOS: Foi aplicado um instrumento genérico 36-Item Short Form Health Survey Questionnaire (SF-36) em 35 pacientes com idade superior a 15 anos, com comprovação clínica e laboratorial ou somente laboratorial de deficiência do inibidor de C1, procedentes de quatro regiões distintas do país. Paralelo a esta medida, foi aplicado um questionário contendo dados pessoais e de história clínica dos pacientes nos últimos seis meses. Com base neste último questionário, foi avaliada a gravidade clínica do AEH através de escore de seis critérios. RESULTADOS: Os pacientes foram preponderantemente do sexo feminino (71,4%), provenientes da zona urbana (85,7%), com nível de escolaridade médio (42,9%) e nível sócio-econômico médio-baixo (57,1%). Em relação à avaliação da QV pelo SF-36, noventa por cento dos pacientes apresentaram escore médio do SF-36 abaixo de 70. Os escores obtidos dos oito domínios tiveram variação de 51,03 a 75,95; sendo os domínios mais comprometidos vitalidade, aspectos sociais e dor. A consistência interna do instrumento foi demonstrada pelo coeficiente alfa de Cronbach acima de 0,7. Não se verificou correlação entre SF-36 médio e os parâmetros sexo, idade, escolaridade, tempo de evolução da doença sem diagnóstico e escore de gravidade clínica considerado neste estudo. CONCLUSÕES: A qualidade de vida dos pacientes com AEH é afetada em vários domínios, porém há necessidade de estudos com questionários doença específicos para melhor caracterização dos prejuízos causados por esta doença em seus portadores. Estas informações poderão ser aplicadas em medidas de promoção da saúde que repercutirão na melhora biopsicosocial destes pacientes / INTRODUCTION: Hereditary angioedema (HAE) is a rare illness, caused by a deficiency of C1 esterase inhibitor (C1-INH), which manifests as recurring unexpected attacks of edema of the face, extremities, genitals, chest and gastrointestinal tract. Edemas in the upper airways can cause asphyxiation and death; while the attacks of abdominal pain can lead to unnecessary laparotomies. Due to its characteristics, HAE deeply affects the quality of life of those affected, physically as well as psychologically and socially. This study aims to evaluate the quality of life related to the health of these patients. METHODS: A generic instrument was applied 36 Item Short Form Health Survey Questionnaire (SF-36) to 35 patients over 15 years of age, with clinical and laboratory evidence or simply laboratory evidence of a deficiency of the C1 inhibitor, from four distinct regions of the country. In addition to this measure, a questionnaire containing personal data and clinical history of the patients in the last six months was applied. Based on this last questionnaire, the clinical severity of the HAE was evaluated through a score of six criteria. RESULTS: The patients were predominantly of female gender (71.4%), from urban areas (85.7%), with an average level of education (42.9%) and medium-low socio-economic level (57.1%). In relation to the evaluation of the QL by SF-36, ninety per-cent of the patients presented average SF-36 scores of below 70. The scores of the eight dimensions showed a variation from 51.03 to 75.95; the most negatively affected scales being vitality, social functioning and pain. The internal consistency of the evaluation was demonstrated by a Cronbach alpha coefficient of above 0.7. No correlation was found between the mean SF-36 scores and the parameters of gender, age, education, duration of the disease without diagnosis and clinical severity score, considered in this study. CONCLUSIONS: The quality of life of the patients with HAE is affected in several domains, however there is a need for studies with disease specific questionnaires to better characterize the damage caused by this disease to its sufferers. This information could be applied in health promotion measures which will have repercussions on the bio-psycho-social improvement of these patients

Sejam K um corpo algebricamente fechado, A uma K-álgebra básica conexa de dimensão finita sobre K e ê=(e_1,e_2,... ,e_n) um conjunto completo de idempotentes ortogonais, primitivos e ordenados de A. O conjunto dos módulos estandares é o conjunto Delta ={ D_1, ..., D_n }, onde D_i é o quociente maximal do A-módulo projetivo P_i com fatores de composição simples S_j, com j\\leq i, F(Delta) é a subcategoria plena de mod A dos módulos têm uma Delta-filtração. Se A_A esta em F(Delta) diz-se que A é uma álgebra estandarmente estratificada. Se, além disso, para cada elemento em Delta vale que End_A(D_i) é isomorfo a K diz-se que A é uma álgebra álgebra quase-hereditária. Nesta dissertação estudamos as propriedades de F(Delta), especialmente quando A é estandarmente estratificada, e algumas condições necessárias e suficientes para que A seja quase-hereditária. / Let K be an algebraically closed field, A a basic, connected, finite dimensional K-algebra and ê=(e_1,e_2,...,e_n) a complete set of ordered primitive orthogonal idempotents of A. The set of standard modules is the set Delta={D_1, ..., D_n}, where D_i is the maximal factor submodule of P_i whose composition factors are isomorphic to S_j, for j\\leq i. We denote by F(Delta) the full subcategory of mod A containing the modules which are filtered by modules in Delta. If iA_A is in F(Delta) we say that A is standardly stratified. Moreover, if End_A(D_i) is isomorphic with K, for each element in Delta we say that A is quasi hereditary. In this work we study the properties of the category F(Delta), especially when A is stardardly stratified, and some necessary and sufficient conditions to A be quasi hereditary.

O angioedema hereditário (AEH) é uma doença autossômica dominante, caracterizada por episódios recorrentes de edema subcutâneo, do trato gastrointestinal e das vias aéreas superiores. Em sua forma clássica, o AEH é causado por deficiência do inibidor de C1 (C1- INH) e está associado a mutações no gene SERPING1. Recentemente, foi descrito o AEH com inibidor de C1 normal, resultante de mutações no gene F12, que codifica o Fator XII da coagulação (FXII), denominado AEH-FXII; e de mutações nos genes PLG e ANGPT1, que codificam Plasminogênio e Angiopoietina-1, caracterizando os tipos AEH-PLG e AEHANGPT1. O AEH com inibidor de C1 normal não cursa com diminuição de C1-INH quantitativo e/ou funcional, ou de C4, sendo o diagnóstico realizado pela presença de sintomas clínicos sugestivos e história familiar. Os objetivos do presente estudo foram: avaliar a discriminação alélica como método alternativo ao sequenciamento por método de Sanger, para o diagnóstico de AEH com inibidor de C1 normal por mutação c.983C>A no gene F12; determinar se a discriminação alélica seria uma técnica de melhor custo-benefício; e investigar outras mutações previamente descritas no exon 9 do gene F12, e nos genes PLG e ANGPT1 em pacientes com suspeita clínica de AEH com inibidor de C1 normal, e negativos para mutação c.983C>A em F12. Cento e oitenta e quatro indivíduos incluindo 51 pacientes- índice com suspeita clínica de AEH com inibidor de C1 normal, e seus familiares, foram previamente investigados por sequenciamento de Sanger. Esses indivíduos foram investigados por discriminação alélica, e a concordância entre os resultados para a mutação c.983C>A foi verificada por estatística Kappa. Custos e tempo de execução entre os dois métodos foram avaliados. Casos-índice negativos para a mutação c.983C>A no gene F12 foram avaliados para outras mutações no exon 9 do gene F12 e para mutações previamente descritas c.988A>G e c.807G>T em PLG e ANGPT1, respectivamente, usando sequenciamento por método de Sanger. Mutação no gene F12 foi identificada em 96 indivíduos (24 pacientes- índice e 72 familiares). Em todos esses pacientes foi encontrada a mutação c.983C>A. 88 indivíduos foram negativos para esta mutação. Os resultados foram 100% concordantes entre os dois métodos. Setenta e um dos 96 pacientes positivos para mutação c.983C>A eram do sexo feminino; 78,9% e 56% eram pacientes sintomáticos do sexo feminino e masculino, respectivamente. A discriminação alélica apresentou custo e tempo de execução 79,7% e 82,3% menores em comparação ao sequenciamento por Sanger, respectivamente. Outras mutações no gene F12, e mutações em PLG e ANGPT1 não foram encontradas. Entre os pacientes negativos para mutações associadas ao AEH com inibidor de C1 normal, 11 foram diagnosticados como AEH-desconhecido e 16 como angioedema idiopático adquirido não histaminérgico. Os resultados do presente estudo nos permitiram construir um algoritmo para diagnóstico de pacientes com AEH com inibidor de C1 normal. Em áreas onde a mutação c.983C>A em F12 é predominante entre pacientes com AEH-FXII, a discriminação alélica pode ser um método adequado para screening inicial. Em pacientes com resultados negativos, sequenciamento do exon 9 de F12 pelo método de Sanger estaria indicado. Pacientes remanescentes com resultados negativos seriam genotipados para mutações previamente descritas em PLG e ANGPT1. Estudos futuros em outros locais serão necessários para estabelecer se a discriminação alélica apresentaria melhor custo-benefício, com potencial para mais acessibilidade ao diagnóstico em pacientes portadores da doença no Brasil / Hereditary angioedema (HAE) is an autosomal dominant disease characterized by recurrent episodes of edema of subcutaneous tissue, gastrointestinal tract, and upper airways. In its classical form, HAE is caused by deficiency of C1 inhibitor (C1-INH) and it is associated with mutations in the SERPING1 gene. Recently, HAE with normal C1 inhibitor has been described, resulting from mutations in F12 gene, which encodes coagulation factor XII (FXII), designated as FXII-HAE; and from mutations in PLG and ANGPT1 genes, which encode Plasminogen and Angiopoietin-1, characterizing PLG-HAE and ANGPT1-HAE types. HAE with normal C1-INH does not present with decrease in quantitative and/or functional levels of C1-INH or C4, and diagnosis is carried out by presence of suggestive clinical symptoms and family history. Diagnosis can only be confirmed by genetic sequencing. The objectives of the present study were: to evaluate the allelic discrimination as an alternative method to sequencing by Sanger method for the diagnosis of HAE with normal C1-INH due to mutation c.983C>A in F12 gene; to determine whether allelic discrimination would be a better cost-effective technique; and to investigate presence of other mutations previously described in exon 9 of F12 gene and in PLG and ANGPT1 genes in patients with clinical suspicion of HAE with normal C1-INH who were negative for c.983C>A mutation in F12. One hundred and eighty-four individuals including 51 index patients with clinical suspicion of HAE with normal C1-INH and their relatives were previously investigated by Sanger sequencing. These individuals were investigated for allelic discrimination, and concordance of the results for the c.983C>A mutation was verified by Kappa statistics. Costs and execution time of the two methods were evaluated. Negative index cases for c.983C>A mutation in F12 gene were evaluated for other mutations in exon 9 of the F12 gene and for mutations previously described c.988A>G and c.807G>T in PLG and ANGPT1, respectively, using sequencing by Sanger method. Mutation in F12 gene was identified in 96 individuals (24 index patients and 72 relatives). In all these patients, the c.983C>A mutation was found. 88 subjects were negative for this mutation. The results were 100% concordant between the two methods. Seventy-one of the 96 patients positive for the c.983C>A mutation were female; 78.9% and 56% were symptomatic female and male patients, respectively. The allelic discrimination presented cost and execution time 79.7% and 82.3% lower in comparison to sequencing by Sanger, respectively. Other mutations in F12 gene, and mutations in PLG and ANGPT1 were not found. Among patients who were negative for mutations associated to HAE with normal C1-INH, 11 were diagnosed as unknown HAE and 16 as idiopathic nonhistaminergic acquired angioedema. The results of present study allowed us to construct an algorithm for diagnosis of patients with HAE with normal C1-INH. In areas where the c.983C>A mutation in F12 is predominant among patients with FXII-HAE, allelic discrimination may be a suitable method for initial screening. In patients with negative results, sequencing of F12 exon 9 by the Sanger method would be indicated. Remaining patients with negative results would be genotyped for mutations previously described in PLG and ANGPT1. Future studies at other sites will be needed to establish whether allelic discrimination would be more cost-effective, with potential for more accessibility to diagnosis in patients with the disease in Brazil

Introdução: A infecção pelo VHC é uma epidemia de proporções globais, que se torna crônica em cerca de 85% dos indivíduos. Sobrecarga de ferro secundária a mutações HFE vem sendo proposta como fator agravante na evolução da hepatite crônica C. Objetivos: Avaliar se sobrecarga de ferro, mutações no gene HFE estão associadas a progressão da fibrose hepática e a carcinoma hepatocelular (CHC) em portadores crônicos VHC. Casuística e Métodos: De um banco de 2300 pacientes matriculados nos Ambulatórios de Hepatologia e de Transplante Hepático do HCFMUSP, selecionaram-se 320 portadores de hepatite crônica C. Os homens (55,6%) apresentaram 50,8 anos de idade em média e as mulheres 54,3. Obtiveram-se dados clínicos e laboratoriais da época da biópsia hepática, admissionais ou com pelo menos um ano de wash-out do tratamento antiviral. Considerou-se sobrecarga bioquímica níveis de ferro, saturação da transferrina e ferritina acima dos valores de referência. Sobrecarga de ferro tecidual foi identificada pela coloração de Perls graus 3-4. As mutações HFE C282Y e H63D foram pesquisadas pela técnica de PCR em tempo real, em DNA extraído de sangue total, após assinatura de TCLE aprovado pelo comitê de ética local. A fibrose hepática foi considerada avançada para graus 3-4 da classificação SBH/SBP e Metavir (n=167, 52,2%). CHC foi definido por biópsia ou por imagem típica por 2 métodos e AFP 400 mg/dL (n=45, 14,1%). Investigaram-se antecedentes de etilismo, diabetes mellitus, IMC e esteatose em biópsia hepática. A partir dos resultados de genotipagem HFE, constituiu-se um subgrupo caso-controle (n=182) com os portadores de mutações e pares de idade, sexo, etnia e IMC similares. Procederam-se análises de correlação bivariada e multivariada (IC=95%) nos grupos geral e caso-controle. Resultados: Quando se compararam casos com fibrose leve vs avançada, observaram-se níveis elevados de ferro em 17,7% vs 25,2% (p=0,019); saturação da transferrina em 24,3% vs 36,7% (p=0,001); ferritina em 25,8% vs 32,4% (p=0,040) e sobrecarga de ferro tecidual em 3,6% vs 1,4% (p=0,126). Quanto à mutação C282Y, observaram-se frequências alélicas de 0,9% vs 2,0% (p=0,110) e à H63D 5,0% vs 8,0% (p=0,033). No subgrupo casocontrole, as associações de C282Y e H63D com fibrose avançada ocorreram com significâncias de p=0,072 e 0,008, respectivamente. A análise multivariada, tendo fibrose como variável dependente nesse mesmo subgrupo, confirmou as associações com C282Y (OR=31,45; p=0,006) e H63D (OR=33,70; p=0,001). Neste mesmo subgrupo, a presença de pelo menos um alelo mutante esteve associada à ocorrência de CHC (p=0,015). Não se identificaram outros parâmetros associados a transformação carcinomatosa. Na análise multivariada, foram variáveis associadas a evolução da fibrose idade avançada (OR=2,36; p=0,000), etilismo (OR=2,18; p=0,007), saturação da transferrina (OR=2,11; p=0,010) e mutação H63D (OR=1,97; p=0,03). Discussão e Conclusões: Houve correlação de graus mais avançados de fibrose com níveis elevados de ferro, saturação da transferrina e ferritina; contudo, esses marcadores também podem estar igualmente elevados nos indivíduos com pouca fibrose. Ao contrário, em muitos casos, a sobrecarga bioquímica de ferro pode ser conseqüência da progressão da doença hepática, e não sua causa. As mutações H63D e C282Y ocorreram em associação com maiores graus de alteração arquitetural; mas, como não houve associação entre siderose tecidual e fibrose, é possível que seu papel na agressão hepática não ocorra diretamente por meio da sobrecarga de ferro. Os portadores de mutações HFE apresentam CHC com maior frequência que seus casos-controle. / Introduction: HCV infection is an epidemic of global proportions, which becomes chronic in about 85% of individuals. Iron overload due to HFE mutations has been proposed as aggravating factor in the evolution of chronic hepatitis C. Objectives: To assess whether iron overload, mutations in the HFE gene are associated with progression of liver fibrosis and hepatocellular carcinoma (HCC) in chronic HCV. Patients and Methods: From a database of 2300 patients enrolled in the outpatient clinics of Hepatology and Liver Transplantation, HCFMUSP, 320 patients with chronic hepatitis C were selected. Men (55.6%) were 50.8 years old on average and women 54.3. Admissional clinical and laboratory data at the time of liver biopsy were obtained; when patient had been previously treated with antiviral drugs, the wash-out period required was of at least one year. Biochemical iron overload was defined as iron, ferritin and transferrin saturation above the reference values. Tissue iron overload was identified by Perls staining of grades 3-4. The HFE C282Y and H63D mutations were searched by real-time PCR technique in DNA extracted from whole blood, after signing of FICT approved by the local ethics committee. The liver fibrosis was considered advanced for grades 3-4 in the classification SBH/SBP and METAVIR(n = 167, 52.2%). HCC was defined by biopsy or by typical image by 2 methods and AFP 400 mg / dL (n = 45, 14.1%). Personal history of alcoholism, diabetes mellitus, BMI and steatosis in liver biopsy were obtained. A casecontrol group was constituted based on the results of HFE genotyping (n = 182), subjects were paired by age, gender, ethnicity and BMI. Bivariate correlation and multivariate analysis (CI = 95%) groups in general and case-control were carried-out. Results: When comparing patients with mild vs advanced fibrosis, biochemical high levels of iron were detected in 17.7% vs 25.2% (p = 0.019), transferrin saturation in 24.3% vs 36.7% (p = 0.001), ferritin in 25.8% vs 32.4% (p = 0.040) and tissue iron overload in 3.6% vs 1.4% (p = 0.126). Regarding to HFE mutations, the allelic frequencies of C282Y were 0.9% vs 2.0% (p = 0.110); and of H63D, 5.0% vs 8.0% (p = 0.033). In casecontrol group, associations of C282Y and H63D with advanced fibrosis occurred with significance of p=0.072 and 0.008, respectively. Multivariate analysis with fibrosis as the dependent variable in that group, confirmed the associations with C282Y (OR = 31.45, p = 0.006) and H63D (OR = 33.70, p = 0.001). In this same subgroup, the presence of at least one mutant allele was associated with occurrence of HCC (p = 0.015). There were not any other parameters found in association with carcinomatous transformation. The multivariate analysis using fibrosis as dependent variable showed association with age (OR = 2.36, p = 0.000), alcoholism (OR = 2.18, p = 0.007), transferrin saturation (OR = 2.11, p = 0.010) and H63D mutation (OR = 1.97, p = 0.03). Discussion and Conclusions: Advanced degrees of fibrosis were correlated with high levels of iron, transferrin saturation and ferritin; however, these markers can also be elevated in individuals with slight fibrosis. In contrary, in many cases, the biochemistry of iron overload may be a consequence of progression of liver disease. C282Y and H63D mutations occurred in association with more advanced fibrosis. However, as there was not any correlation between tissue siderosis and fibrosis, it might be possible that liver injury occurs not by the iron overload pathway. Finally, carriers of HFE mutations were found with HCC more frequently than their casecontrol.

Next-Generation Sequencing has opened the doors to nearly limitless amounts of genomic data, but the clinical utility of this data is not yet clear. From examining at sequencing data of known familial cancer genes in hereditary cancer patients, the NCGENES study found a clear molecular diagnosis in about 5% of patients and an uncertain molecular result in about 15% of patients. The remaining 80% of hereditary cancer patients received a negative result for the screening of known cancer genes. These latter patients were followed up by whole exome sequencing analysis, and the data was used to perform a research sweep to potentially identify mutation(s) in gene(s) that have yet to be clearly associated with their phenotype. Hereditary breast cancer has a relatively well-established set of susceptibility genes, yet a large percentage of the molecular etiology is still unknown. There are many genes that are good candidates for breast cancer genes based on their protein's function, but they may not actually contribute to breast cancer susceptibility. The ClinGen consortium is aiming to establish the clinical validity of gene-disease associations so that clinicians and patients can better interpret and utilize sequencing results. Six breast cancer susceptibility genes were evaluated using the ClinGen clinical validity framework with the goal of both evaluating the genes already on hereditary breast cancer panels and evaluating genes not yet widely tested to determine if there is enough evidence to support their role in disease to warrant widespread testing. These genes have varying levels of evidence supporting their role in breast cancer susceptibility. The variants in each of the six genes were compared between a cancer patient cohort and a non-cancer patient cohort enrolled in the NCGENES whole exome sequencing study. One likely pathogenic variant and several variants of unknown significance were identified in various genes, and the burden of variants in cancer cases versus controls was evaluated, although the controls were not matched to the cancer cohort in any way. Research sweeps were performed for patients with VUSs to ensure that there were no other mutations in genes that would better fit the phenotype. This thesis presents a method for evaluating gene-disease associations and for utilizing whole exome sequencing data to pinpoint a molecular diagnosis in hereditary breast cancer patients. Overall, it was found that the ClinGen method of evaluating clinical validity of gene-disease associations could be helpful when determining if variants are pathogenic or benign. A new gene, RINT1, was found to have enough evidence to be moderately associated with hereditary breast cancer and it was subsequently added to the diagnostic list so that all cancer patients will now be screened for RINT1 variants. In addition, it was found that two of the genes currently on the diagnostic list, RAD51C and RAD51D, have "disputed" evidence with respect to breast cancer susceptibility. Interestingly, they have much more evidence for an association with ovarian cancer, so if variants are found in these genes, the patient's phenotype should be considered when evaluating them. It was also shown that PALB2, an established breast cancer susceptibility gene, indeed is definitively associated with breast cancer, and the NCGENES cancer patients have more truncating variants than the controls, further validating the clinical validity assertion. Finally, an ovarian cancer patient with two interesting variants, one in SLX4 and one in GEN1, were evaluated. Studies showed that knocking out both of these genes' pathways was highly destructive to the cell. A VUS was found in each of these genes, and it was hypothesized that perhaps these two variants together may be sufficient to contribute to this patient's cancer susceptibility.

Vesicle trafficking provides the solution to the 'sorting problem' - how the eukaryotic cell maintains the distinct identities, and thus functional properties, of its membrane-bound organelles. During vesicle trafficking, proteins are selectively sorted into membrane bound transport intermediates by vesicle adaptors, which include those of the highly conserved adaptor protein (AP) complex family. Each AP complex has a distinct subcellular localisation and functions in the sorting of a specific subset of transmembrane cargo proteins. Adaptor protein complex 4 (AP-4) is one of the more recently identified AP complexes, whose function has largely remained elusive. In humans, AP-4 deficiency causes a severe neurological disorder, suggesting an important role in neuronal development and homeostasis. However, the pathomechanisms that underly the neuronal pathology in AP-4 deficiency are currently unknown. AP-4 is proposed to function in protein sorting at the trans-Golgi network (TGN), so AP-4 deficiency can be thought of as a disease of missorting. The aim of this study was to apply unbiased global proteomic approaches to define the composition of AP-4 vesicles and to identify physiological cargo proteins of the AP-4 pathway. Using 'Dynamic Organellar Maps' and comparative analysis of vesicle-enriched fractions from wild-type and AP-4-depleted cells, three ubiquitously expressed transmembrane cargo proteins, ATG9A, SERINC1 and SERINC3, were found to be mislocalised in AP-4-deficient cells. Two novel cytosolic AP-4 accessory proteins, RUSC1 and RUSC2, were also identified. Further proteomic analyses confirmed the interactions between these proteins. AP-4 deficiency was found to cause missorting of ATG9A in diverse cell types, including patient derived cells, as well as dysregulation of autophagy. RUSC2 facilitates the transport of AP-4-derived, ATG9A and SERINC-positive vesicles from the TGN to the cell periphery. These vesicles cluster in close association with autophagosomes, suggesting they are the 'ATG9 reservoir' required for autophagosome biogenesis. This study uncovers ATG9A trafficking as a ubiquitous function of the AP-4 pathway. Furthermore, it provides a potential molecular pathomechanism of AP-4 deficiency, through dysregulated spatial control of autophagy.